https://eureka.patsnap.com/resources/blog/rd-blog/full-empty-capsid-separation-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Viral Vector Manufacturing
Full Empty Capsid Separation Patents: Who Leads and Where the Field Is Still Open
  • Concentrated at the top. The top 5 assignees hold 80.8% of all 52 records in scope, with the leader alone accounting for 15 records.
  • Filings peaked in 2022 at 19 records, then eased to 6 by 2024 (-14% from 2021's 7) — though 2025-26 counts are still filling in as publications lag filing.
  • Purification method claims dominate technology mix, with B01D separation processes appearing in 30.8% of records alongside heavy overlap in C07K and C12N classes.
Get a prior-art report on your approach
52
Published Records
81%
Top-5 Share of All Records
-14%
Filing Growth 2021→2024
WO
Leading Jurisdiction

Filing growth compares 2021 (7 records) with 2024 (6) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 52 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Field Overview

What separates full from empty capsids, and who is patenting it

Full/empty capsid separation addresses a persistent bottleneck in AAV-based gene therapy manufacturing: distinguishing genome-containing ("full") capsids from empty shells that carry no therapeutic payload. The dominant patented routes are anion exchange chromatography (AEX), density-gradient methods, and analytical assays used to quantify capsid content and set process specifications. Records in this dataset span 2015 to mid-2026, drawing on 52 published families that combine purification chemistry with therapeutic and genetic-engineering classifications.

The field sits at the intersection of separation science and biologics manufacturing scale-up, which is why the same records frequently carry both a separation-process class and a therapeutic-activity class. That overlap is a filing pattern, not evidence of technology maturity — dense claim coverage in one class does not mean the underlying process is settled science.

Filing activity and technology mix, 2015-2026
  1. 1CSL Behring AG15
  2. 2Ankyra Therapeutics10
  3. 3Pfizer Inc.9
  4. 4Amgen Inc.4
  5. 5North Carolina State University4
  6. 6OXFORD BIOMEDICA SOLUTIONS LLC3
  7. 7Homology Medicines2
  8. 8Regeneron Pharmaceuticals2
  9. 9Oxford Biomedica (US) LLC1
  10. 10CSL Behring AG1
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Let an AI agent run this analysis on your own technology

Pick a task. Every answer cites the patents behind it.

10,000 free credits to start
The Numbers

Filing trend and technology composition

Two views of the same 52-record dataset: how filing activity has moved year over year, and which IPC subclasses the records fall into.

Filing trend, 2017-2026

Filings rose to a peak of 19 records in 2022, then declined to 6 by 2024 — a -14% move from 2021's 7 records over that three-year span. 2025 and 2026 figures are still incomplete because publication typically lags filing by around 18 months, so the apparent tail-off should not be read as the field cooling.

Filing trend, 2017-20260510152002017201820192020202119202220232024202502026Most recent year is partial — publication lag means later filings are not yet visible.

Technology composition by IPC subclass

C07K (peptides & proteins) appears in 65.4% of the 52 records, followed by C12N (microorganisms & genetic engineering) at 51.9% and A61P (therapeutic activity) at 46.2%. B01D, the class most tied to physical separation processes, appears in 30.8% of records. Because records can carry multiple classes, these shares sum to well over 100% and should not be read as mutually exclusive segments.

Technology composition by IPC subclassC07K · Peptides & proteins3465.4%C12N · Microorganisms & genetic engin…2751.9%A61P · Therapeutic activity of compou…2446.2%A61K · Medicinal preparations2344.2%B01D · Separation processes (filtrati…1630.8%G01N · Material analysis & testing35.8%

Shares are the percentage of the 52 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Full Empty Capsid Separation with Eureka

This page is one run against one query. Ask Eureka your own question about full empty capsid separation and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

The most-cited records in this dataset

Representative Filing
WO2024038365A12024-02-22

Methods for purification of AAV vectors by anion exchange chromatography

PFIZER INC.

The present disclosure provides methods for purifying a recombinant AAV (rAAV) vector from a solution by anion-exchange chromatography (AEX) to produce an eluate enriched for full capsids and depleted of empty capsids.Filed by Pfizer, published 2024-02-22 as WO2024038365A1.

WO2024038365A1 — patent drawing 1WO2024038365A1 — patent drawing 2
View full filing
Most-cited patent families
#Publication no.Patent titleCitations
1WO2023077086A1Methods and compositions for the purification of adeno-associated virus5
2WO2023077085A2Methods and compositions for the purification of adeno-associated virus3
3WO2022137076A1Methods for purification of AAV vectors by affinity chromatography3
4WO2023007445A1Method of purifying immunoglobulin g and uses thereof2
5WO2024038365A1Methods for purification of AAV vectors by anion exchange chromatography1
6US20230183658A1Methods and compositions for the purification of adeno-associated virus1

Citation counts reflect influence within the searched corpus and skew toward older filings — treat them as a signal of prior-art density, not of current commercial importance.

Publication numbers are shown where the record carries one (6 of 6 rows); clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis


  
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the filing pattern tells you

Reading the concentration, trend, and citation data together points to where claim space is occupied and where it is not.

Concentration
80.8% of 52 records
held by top 5 assignees

Coverage sits with a small group

With the leader alone holding 15 of 52 records and the top 5 combined controlling 80.8% of the field, new entrants are filing into territory already staked out by a handful of biologics manufacturers and CDMOs.

Top 10 combined reach 98.1% of records.
Peak & Pullback
19 records in 2022
peak filing year

Activity crested, then cooled — with a caveat

Filings ran from 0 in 2017 to a peak of 19 in 2022, then measured -14% from 2021 (7) to 2024 (6). Because publication lags filing by roughly 18 months, 2025-26 figures are not yet a reliable read on current appetite.

2024 is the most recent year treatable as complete.
Method Focus
30.8% of records
carry B01D separation-process claims

Physical separation claims are a minority alongside biologics classes

B01D appears in under a third of records, while C07K, C12N, A61P and A61K each cover a much larger share. Purification-specific claims are outnumbered by the broader biologics and therapeutic classifications wrapped around them.

Shares overlap because records carry multiple IPC classes.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to full empty capsid separation, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who holds the ground, and where it thins out

Ten assignees make up the entire ranked field returned for this dataset — not a top-50 or top-100 cut, but the whole list the data endpoint returns for these 52 records.

Leader
15 records
of 52 in scope

A single assignee holds the largest share

The top-ranked assignee alone accounts for 15 of the 52 records in scope, well ahead of the field, and recent-year momentum data shows 0 filings in the latest year across the tracked assignees — consistent with the publication-lag effect rather than a sudden stop in activity.

See the full ranking table for names and counts.
Mid-Field
4 records
fifth-place assignee

A steep drop after the leader

Fifth place holds 4 records versus the leader's 15, and the tenth-ranked assignee holds just 1 — a sharp taper that leaves a long tail of single- or low-filing entrants beneath the top handful.

Top 10 combined cover 98.1% of all records.
Receiving Offices
11 filings
via WIPO (PCT)

PCT filing leads, with EPO and US close behind

WIPO (PCT) receives the largest single share of filings at 11, followed by Europe and the United States at 6 each, then Australia and Israel at 4 and Canada at 3 — indicating applicants are seeking broad multi-jurisdiction cover rather than filing nationally first.

Office counts reflect where applications were received, not where inventions originated.
🔍
Under-claimed sub-areas worth a closer look
Branches with comparatively thin direct coverage relative to the core purification claims above.
real-time capsid ratio in-line sensingbuffer conductivity gradient optimizationscalable AEX alternatives to ultracentrifugationorthogonal capsid content assay validationcontinuous-flow polishing steps
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
CSL Behring AG0—
Ankyra Therapeutics0-100%
Pfizer Inc.0—
Amgen Inc.0—
North Carolina State University0—
OXFORD BIOMEDICA SOLUTIONS LLC0—
Homology Medicines0—
Regeneron Pharmaceuticals0-100%
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this analysis

The concentration and technology-mix data point to specific next steps depending on what you're trying to decide.

Map claim scope against the leader's portfolio

With one assignee holding 15 of 52 records, any new filing in AEX polishing or capsid content assays should be checked against that portfolio's specific claim language before drafting.

Explore assignee portfolios in Eureka

Watch the under-claimed branches

Real-time capsid ratio sensing and buffer conductivity optimization show thinner direct coverage than the core separation-process claims, suggesting room for a well-drafted first claim.

Run a white-space search in Eureka

Track the 2025-26 filing tail as it fills in

Because publication lags filing by roughly 18 months, the apparent 2024 pullback needs re-checking once later years complete.

Set a filing alert in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions on full/empty capsid separation patents

Answers are grounded in the same dataset. Derived from a Patsnap search on Full Empty Capsid Separation covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Full Empty Capsid Separation in depth with Eureka

Go past this page: query the whole full empty capsid separation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve

Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.